Pre-Pregnancy GLP-1 Receptor Agonist or Tirzepatide Use and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry-Over Versus Post-Discontinuation Metabolic Rebound in a Multinational Federated Cohort.
Tirzepatide: Timing Matters for Gestational Diabetes Risk
Diabetes Obes Metab
by Banerjee M, Dutta S, Dasgupta S
“Pre-Pregnancy GLP-1 Receptor Agonist or Tirzepatide Use and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry-Over Versus Post-Discontinuation Metabolic Rebound in a Multinational Federated Cohort. Banerjee M(1)(2), Dutta S(3), Dasgupta S(4). Author information: (1)Department of Endocrinology, R. N. Tagore Hospital, Narayana Health, Kolkata, India. (2)Department of Endocrinology, Ramakrishna Mission Seva Pratisthan Vivekananda Institute of Medical Sciences, Kolkata, India. (3)Department of Neonatology, Institute of Post Graduate Medical Education & Research, Kolkata, India. (4)Department of Reproductive Medicine, Genome Fertility Centre, Kolkata, India. AIM: To evaluate the association between preconception glucagon-like peptide-1 receptor agonist (GLP-1RA)/tirzepatide use and the risk of gestational diabetes mellitus (GDM). METHODS: This retrospective cohort study (January 1, 2015-April 30, 2025) utilised the TriNetX multinational network. Women (18-45 years) without pre-existing diabetes were propensity score-matched 1:1 on demographics, numerical BMI, HbA1c and comorbidities. The primary cohort examined preconception GLP-1RA/tirzepatide use 6-18 months before index pregnancy encounter with pre-pregnancy (> 90 days pre-index) discontinuation. Secondary analysis evaluated abrupt discontinuation (prescription issuance ≤ 90 days pre-index). Risk ratios (RR) were estimated in matched cohorts. RESULTS: When matched for pre-pregnancy BMI, preconception GLP-1RA/tirzepatide use was associated with a GDM risk comparable to non-users (N = 892; 16.3% vs. 16.8%; RR: 0.967; 95% CI: 0.719-1.315), despite a higher gestational BMI rebound (+1.8 vs. +1.2 kg/m2; excess gain + 0.6 kg/m2). Conversely, abrupt discontinuation was associated with a 53% increase in GDM risk (N = 578; RR: 1.536; 95% CI 1.020-1.955; p = 0.039), likely driven by a steeper BMI rebound (excess gain + 1.3 kg/m2). Sensitivity analysis, matched on pre-treatment window, confirmed similar GDM incidence despite higher residual mean BMI in treated women (37.0 vs. 35.0 kg/m2; RR: 0.988, 95% CI 0.701-1.378). CONCLUSIONS: Preconception GLP-1RA or tirzepatide therapy with pre-pregnancy discontinuation was associated with GDM risk comparable to BMI-matched unexposed women despite a modest BMI rebound. However, abrupt discontinuation close to conception conferred a 53% higher GDM risk, indicating that any pharmacodynamic carry-over effect is contingent upon the discontinuation timing and velocity of weight rebound during gestation, rather than preconception exposure itself. Pending confirmation in prospective studies, these findings identify the post-withdrawal window and subsequent weight rebound as targets for preconception care strategies to preserve a potential residual metabolic benefit in women receiving incretin-based therapy. © 2026 John Wiley & Sons Ltd.”
Researchers just dropped a big dataset on pre-pregnancy tirzepatide and GLP-1 receptor agonist use. The goal: figure out if using these peptides before conception changes the odds of developing gestational diabetes (GDM) later on. They pulled data from a multinational network, looking at women aged 18-45 without pre-existing diabetes.
Here’s the punchline: If tirzepatide or a GLP-1 RA was stopped at least 90 days before pregnancy, GDM risk stayed about the same compared to women who never used these peptides (16.3% vs. 16.8%). This held true even though there was a bit of a BMI rebound after stopping — about 0.6 kg/m2 more weight gain. But if the peptide was stopped close to conception (within 90 days), GDM risk shot up by 53%. That group also saw a steeper BMI increase.
Key takeaway: The “when” of discontinuing tirzepatide or GLP-1RAs matters more than “if” you use them before pregnancy. The risk isn’t about having used these peptides, but about how quickly the body rebounds in weight after stopping — especially right before or during early pregnancy.
Why does this matter for peptide researchers? It’s another example of how peptide timing and post-discontinuation effects can shape real-world outcomes. The metabolic benefit seems to linger if you space things out, but abrupt withdrawal ramps up risk.
For anyone working on study protocols or exploring new incretin-based strategies, keep an eye on the post-withdrawal window. The rebound effect is real and may offer a research target for maximizing benefit.
Check out the full tirzepatide profile for more data, or browse the vendor directory for sourcing options. Timing is everything in peptide research.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.